🇺🇸 recombinant human interleukin-21 in United States
2 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 2
Most-reported reactions
- Gastrointestinal Disorder — 1 report (50%)
- Haematotoxicity — 1 report (50%)
Frequently asked questions
Is recombinant human interleukin-21 approved in United States?
recombinant human interleukin-21 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for recombinant human interleukin-21 in United States?
NCIC Clinical Trials Group is the originator. The local marketing authorisation holder may differ — check the official source linked above.